Fermentation properties and potential prebiotic activity of Bimuno® galacto-oligosaccharide (65 % galacto-oligosaccharide content) on in vitro gut microbiota parameters
- PMID: 27267934
- PMCID: PMC4937186
- DOI: 10.1017/S0007114516002269
Fermentation properties and potential prebiotic activity of Bimuno® galacto-oligosaccharide (65 % galacto-oligosaccharide content) on in vitro gut microbiota parameters
Abstract
Prebiotic oligosaccharides have the ability to generate important changes in the gut microbiota composition that may confer health benefits to the host. Reducing the impurities in prebiotic mixtures could expand their applications in food industries and improve their selectivity and prebiotic effect on the potential beneficial bacteria such as bifidobacteria and lactobacilli. This study aimed to determine the in vitro potential fermentation properties of a 65 % galacto-oligosaccharide (GOS) content Bimuno® GOS (B-GOS) on gut microbiota composition and their metabolites. Fermentation of 65 % B-GOS was compared with 52 % B-GOS in pH- and volume-controlled dose-response anaerobic batch culture experiments. In total, three different doses (1, 0·5 and 0·33 g equivalent to 0·1, 0·05 and 0·033 g/l) were tested. Changes in the gut microbiota during a time course were identified by fluorescence in situ hybridisation, whereas small molecular weight metabolomics profiles and SCFA were determined by 1H-NMR analysis and GC, respectively. The 65 % B-GOS showed positive modulation of the microbiota composition during the first 8 h of fermentation with all doses. Administration of the specific doses of B-GOS induced a significant increase in acetate as the major SCFA synthesised compared with propionate and butyrate concentrations, but there were no significant differences between substrates. The 65 % B-GOS in syrup format seems to have, in all the analysis, an efficient prebiotic effect. However, the applicability of such changes remains to be shown in an in vivo trial.
Keywords: B-GOS Bimuno galacto-oligosaccharide; Bimuno® galacto-oligosaccharides; Fluorescence in situ hybridisation; GOS galacto-oligosaccharide; Microbiota composition; Prebiotic activity; SCFA.
Figures







Similar articles
-
Galacto-oligosaccharides have prebiotic activity in a dynamic in vitro colon model using a (13)C-labeling technique.J Nutr. 2012 Jul;142(7):1205-12. doi: 10.3945/jn.111.157420. Epub 2012 May 23. J Nutr. 2012. PMID: 22623395
-
Combinational effects of prebiotic oligosaccharides on bifidobacterial growth and host gene expression in a simplified mixed culture model and neonatal mice.Br J Nutr. 2016 Jul;116(2):270-8. doi: 10.1017/S0007114516001987. Epub 2016 May 20. Br J Nutr. 2016. PMID: 27198516
-
A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age.Br J Nutr. 2012 May;107(10):1466-75. doi: 10.1017/S0007114511004697. Epub 2011 Sep 13. Br J Nutr. 2012. PMID: 21910949 Clinical Trial.
-
Prebiotic effects: metabolic and health benefits.Br J Nutr. 2010 Aug;104 Suppl 2:S1-63. doi: 10.1017/S0007114510003363. Br J Nutr. 2010. PMID: 20920376 Review.
-
Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders.J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:64-68. doi: 10.1111/jgh.13700. J Gastroenterol Hepatol. 2017. PMID: 28244671 Review.
Cited by
-
Chronic consumption of a blend of inulin and arabinoxylan reduces energy intake in an ad libitum meal but does not influence perceptions of appetite and satiety: a randomised control-controlled crossover trial.Eur J Nutr. 2023 Aug;62(5):2205-2215. doi: 10.1007/s00394-023-03136-6. Epub 2023 Apr 12. Eur J Nutr. 2023. PMID: 37046122 Clinical Trial.
-
Alpha-Galacto-Oligosaccharides at Low Dose Improve Liver Steatosis in a High-Fat Diet Mouse Model.Molecules. 2017 Oct 14;22(10):1725. doi: 10.3390/molecules22101725. Molecules. 2017. PMID: 29036913 Free PMC article.
-
Daily consumption of galactooligosaccharide gummies ameliorates constipation symptoms, gut dysbiosis, degree of depression and quality of life among sedentary university teaching staff: A double-blind randomized placebo control clinical trial.Indian J Gastroenterol. 2023 Dec;42(6):839-848. doi: 10.1007/s12664-023-01435-8. Epub 2023 Sep 26. Indian J Gastroenterol. 2023. PMID: 37751049 Clinical Trial.
-
Effects of the Administration of Bifidobacterium longum subsp. infantis CECT 7210 and Lactobacillus rhamnosus HN001 and Their Synbiotic Combination With Galacto-Oligosaccharides Against Enterotoxigenic Escherichia coli F4 in an Early Weaned Piglet Model.Front Microbiol. 2021 Apr 16;12:642549. doi: 10.3389/fmicb.2021.642549. eCollection 2021. Front Microbiol. 2021. PMID: 33935999 Free PMC article.
-
Preventive Effect of a Synbiotic Combination of Galacto- and Fructooligosaccharides Mixture With Bifidobacterium breve M-16V in a Model of Multiple Rotavirus Infections.Front Immunol. 2018 Jun 11;9:1318. doi: 10.3389/fimmu.2018.01318. eCollection 2018. Front Immunol. 2018. PMID: 29942312 Free PMC article.
References
-
- Sangwan V, Tomar SK, Singh RRB, et al. (2011) Galactooligosaccharides: novel components of designer foods. J Food Sci 76, 103–111. - PubMed
-
- Tzortzis G & Vulevic J (2009) Galacto-oligosaccaride prebiotics. Prebiotics Probiotics Sci Technol 1, 207–244.
-
- Hernandez O, Ruiz-Matute AI, Olano A, et al. (2009) Comparison of fractionation techniques to obtain prebiotic galactooligosaccharides. Int Dairy J 19, 531–536.
-
- Tzortzis G (2009) Development and functional properties of Bimuno: a second-generation prebiotic mixture. Food Sci Technol Bull 6, 81–89.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous